Pharma Pipelines Filling, Firms Say; New Fear Is “Bottleneck” In Early Stage
Executive Summary
Large pharma companies are facing a potential "bottleneck" in early stage clinical development as they sift through new therapeutic candidates, Merck Exec VP-Worldwide Basic Research Anthony Ford-Hutchinson, PhD, told a BIO-Windhover conference April 15 in Washington, D.C
You may also be interested in...
Pharma Firms Debate Novel Biotech Deals: How Much Competition Is Healthy?
R&D productivity is best encouraged through "benchmarking" among a firm's own drug development centers rather than external competition with licensing partners, Merck Exec VP-Worldwide Basic Research Anthony Ford-Hutchinson, PhD, said
Pharmacogenomics Moves Into Spotlight With Completion Of Genome Project
Industry is ready to "embrace" pharmacogenomic-based drug development as long as commercial and regulatory applications are based on a full understanding of the technology, AstraZeneca VP-Clinical Development Glenn Gormley, MD/PhD, said during FDA's risk management public workshop April 9
Pharma Firms Debate Novel Biotech Deals: How Much Competition Is Healthy?
R&D productivity is best encouraged through "benchmarking" among a firm's own drug development centers rather than external competition with licensing partners, Merck Exec VP-Worldwide Basic Research Anthony Ford-Hutchinson, PhD, said
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: